A Multicenter, Randomized, Double-Blind, PlaceboControlled, Operationally Seamless, Adaptive Phase 2/3Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very SevereAlopecia Areata

Project: Research project

Description

A Multicenter, Randomized, Double-Blind, PlaceboControlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata
StatusActive
Effective start/end date8/6/188/30/23

Funding

  • Eli Lilly and Company

Fingerprint

Alopecia Areata
Safety
baricitinib